Tumour Ablation for Liver Cancer: What to Expect at Home Bookmark

Ablation therapy is becoming common practice for treatment of cancer that begins in the liver. MyHealth.Alberta.ca provides information on recovery and at-home care following the procedure.

A Phase I Study of Telomelysin Added to Chemoradiation for Patients with Advanced Inoperable Esophageal Cancer Bookmark

Memorial Sloan Kettering Cancer Center recently began recruiting patients for a phase 1 clinical trial to test a treatment in which an investigational cancer cell-killing virus called Telomelysin is directly injected into inoperable esophageal cancer tumors. Participating patients will receive this “cancer vaccine” alongside standard chemoradiation therapy.

.

Opdivo Approved in Europe as Second-line Therapy for Advanced Esophageal Cancer Bookmark

Immuno-Oncology News reports on the European Commission’s approval of the drug nivolumab (Opdivo) for some patients with advanced esophageal cancer.

.

Léon C. van Kempen, PhD, on a Successful Molecular Tumor Board in NSCLC Bookmark

This article from MedPage Today discusses recent study findings demonstrating that patients with complex cases of non-small cell lung cancer can benefit from the insights of a molecular tumor board.

.

Olaparib Granted Positive EU Opinion for BRCA1/2+ Advanced Prostate Cancer Bookmark

A news story published by OncLive reports that the European Union’s Committee for Medicinal Products for Human Use recently approved the drug olaparib for treating patients with a subset of advanced castrate-resistant prostate cancers that have BRCA1/2 mutations.

.

For Esophageal Cancer, Immunotherapy Likely to Play Larger Role Bookmark

A blog post from the National Cancer Institute reports that two clinical trials are showing encouraging results for progression-free survival—and one for overall survival—from treatment with immunotherapy drugs in people with advanced esophageal cancer. 

.

Two New Treatments Approved For Advanced Prostate Cancer Bookmark

A story published by the Prostate Cancer Foundation outlines two new treatment options approved by the U.S. Food and Drug Administration (FDA) this year. The two medications, rucaparib and olaparib, each target specific mutations that may be found in a patient’s tumor, and each was approved for a specific type of prostate cancer.

.

Cancer Vaccine UV1 Plus Keytruda Shows Safety, Early Efficacy in Advanced Melanoma Trial Bookmark

A story from Immuno-Oncology News covers new results from a phase 1 clinical trial that indicate promising safety and early efficacy of a treatment that combines the drug Keytruda and an experimental cancer vaccine for people with advanced melanoma.

.

Efficacy and Safety of Nivolumab Plus Ipilimumab in Patients With Advanced Hepatocellular Carcinoma Previously Treated With Sorafenib Bookmark

This scientific research paper published in JAMA Oncology reports results from a clinical trial in which the drugs nivolumab and ipilimumab showed promising safety and efficacy for people with advanced liver cancer who had previously received the drug sorafenib.

.

Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma Bookmark

This academic research paper from The New England Journal of Medicine reports results from a clinical trial in which a treatment that combines the drugs atezolizumab and bevacizumab improved both progression-free and overall survival for people with unresectable primary liver cancer.

.